Article
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Molecular cancer therapeutics - 1 Oct 2012
Nakagawa Takayuki, Takeuchi Shinji, Yamada Tadaaki, Nanjo Shigeki, Ishikawa Daisuke, Sano Takako, Kita Kenji, Nakamura Takahiro, Matsumoto Kunio, Suda Kenichi, Mitsudomi Tetsuya, Sekido Yoshitaka, Uenaka Toshimitsu, Yano Seiji
Abstract excerpt
Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown dramatic effects against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper EGFR-T790M mutation, Met amplification, and HGF overexpression, thereafter relapsing. Thus, it is urgent to develop novel agents to overcome EGFR-TKI resistance. We have tested the effects of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.